Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company focused on precision medicine for Alzheimer's and other age-related diseases, has announced that the U.S. Food and Drug Administration

Axxam S.p.A. and Momentum Biotechnologies have recently formed a partnership to deliver innovative drug discovery solutions for clients in the biotechnology and pharmaceutical industries. The collaboration involves making Axxam's

Athira Pharma, Inc., recently unveiled promising preclinical data on fosgonimeton, a potential breakthrough in the treatment of Alzheimer's disease and other neurodegenerative conditions.

Ardelyx, Inc., is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines to address unmet medical needs. The company recently announced that the U.S. Food and Drug Administration

Alvotech and JAMP Pharma Group have jointly announced that Health Canada has granted marketing authorization to JAMP Pharma for AVT04, a biotech analogue of Stelara (ustekinumab) developed by Alvotech.

Cerevance, a company dedicated to advancing precision therapeutics for central nervous system disorders, has recently initiated the Phase 2 clinical study of CVN424 in individuals diagnosed with early-stage Parkinson's disease

Legend Biotech Corporation has recently announced a significant development - its wholly-owned subsidiary, Legend Biotech Ireland Limited, has entered into an exclusive global license agreement with Novartis Pharma AG

Alvotech and STADA Arzneimittel have received a favorable opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency

Andelyn Biosciences, Inc., a forward-thinking Contract Development and Manufacturing Organization

BioRay Pharmaceutical Co. has commenced the Phase I clinical trial for BRY812, an innovative antibody-drug conjugate targeting LIV-1, a zinc transporter associated with cell growth in advanced malignancies.